Table 2.
Yield of referable eye disease by year of screening
| Yield of referable eye disease n (%) | |||||
|---|---|---|---|---|---|
| 2006 (n=39 463) | 2007 (n=117 348) | 2008 (n=128 897) | 2009 (n=128 203) | 2010 (n=130 170) | |
| No eye disease | 24 734 (62.7) | 76 818 (65.5) | 87 184 (67.6) | 85 676 (66.8) | 88 019 (67.6) |
| Non-referable eye disease | 11 950 (30.3) | 33 524 (28.6) | 36 197 (28.1) | 36 956 (28.8) | 36 500 (28.0) |
| Referable eye disease | 2779 (7.0) | 7006 (6.0) | 5516 (4.3) | 5571 (4.3) | 5651 (4.3) |
| Referable maculopathy alone | 1666 (4.2) | 4587 (3.9) | 3805 (3.0) | 3993 (3.1) | 4107 (3.2) |
| Referable background retinopathy±maculopathy | 716 (1.8) | 1452 (1.2) | 978 (0.8) | 800 (0.6) | 751 (0.6) |
| Proliferative retinopathy±maculopathy | 397 (1.0) | 967 (0.8) | 733 (0.6) | 778 (0.6) | 793 (0.6) |
Referable eye disease comprises referable maculopathy (M2 on the DRS grading scheme), preproliferative retinopathy (R3 on the DRS grading scheme) and proliferative retinopathy (R4 on the DRS grading scheme).
DRS, Diabetic Retinopathy Screening service.